BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma

Autophagy is a resistance mechanism to BRAF/MEK inhibition in BRAFV600-mutant melanoma. Here we used hydroxychloroquine (HCQ) to inhibit autophagy in combination with dabrafenib 150 mg twice daily and trametinib 2 mg every day (D+T). We conducted a phase I/II clinical trial in four centers of HCQ +...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research Jg. 28; H. 6; S. 1098
Hauptverfasser:	Mehnert, Janice M, Mitchell, Tara C, Huang, Alexander C, Aleman, Tomas S, Kim, Benjamin J, Schuchter, Lynn M, Linette, Gerald P, Karakousis, Giorgos C, Mitnick, Sheryl, Giles, Lydia, Carberry, Mary, Frey, Noelle, Kossenkov, Andrew, Groisberg, Roman, Hernandez-Aya, Leonel F, Ansstas, George, Silk, Ann W, Chandra, Sunandana, Sosman, Jeffrey A, Gimotty, Phyllis A, Mick, Rosemarie, Amaravadi, Ravi K
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 15.03.2022
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Autophagy Humans Hydroxychloroquine - therapeutic use Imidazoles Melanoma - drug therapy Melanoma - genetics Melanoma - pathology Mitogen-Activated Protein Kinase Kinases Mutation Oximes - therapeutic use Proto-Oncogene Proteins B-raf - genetics Pyridones - therapeutic use Pyrimidinones - therapeutic use
ISSN:	1557-3265, 1557-3265
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!